New York: A new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, new research has found.
The drug palbociclib targets the rapid division of tumour cells by inhibiting the activity of the enzymes CDK4 and CDK6, which propel cell division and increase in number in most cancers, the study said.
"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability," said the study's lead author Amy Clark, assistant professor at Perelman School of Medicine, University of Pennsylvania in the US.
"Pairing palbociclib with other anti-cancer therapies such as endocrine therapy, chemotherapy, and targeted therapy can create a powerful combinatorial effect with real promise for addressing a variety of cancers," Ms Clark noted.
Assessing 130 relevant publications in the literature, as well as interpreting their own continuing studies, the research team found that in addition to its safety and effectiveness in fighting certain types of breast cancer, early trials of palbociclib have shown promise of effectiveness in cases of lymphoma, sarcoma, and teratoma, tumours that while rare, often afflict younger patients.
In both breast and other cancer trials, palbociclib has been shown to be safe with once-daily dosing, and its main adverse effect is reversible neutropenia, an abnormally low count of neutrophils, a type of white blood cell that helps fight infections.
"This drug has minor effects on normal cells other than neutrophils (white blood cells)," study senior author, Peter O'Dwyer, professor at University of Pennsylvania, noted.
"In tumours, it can cause shrinkage, or more commonly, arrest of growth. As we discover new functions for the CDK4/6 target of this medicine, we are likely to use it in combinations to make other anti-cancer agents work better," Mr O'Dwyer said.
The study was published in the journal JAMA Oncology.
The drug palbociclib targets the rapid division of tumour cells by inhibiting the activity of the enzymes CDK4 and CDK6, which propel cell division and increase in number in most cancers, the study said.
"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability," said the study's lead author Amy Clark, assistant professor at Perelman School of Medicine, University of Pennsylvania in the US.
Assessing 130 relevant publications in the literature, as well as interpreting their own continuing studies, the research team found that in addition to its safety and effectiveness in fighting certain types of breast cancer, early trials of palbociclib have shown promise of effectiveness in cases of lymphoma, sarcoma, and teratoma, tumours that while rare, often afflict younger patients.
Advertisement
"This drug has minor effects on normal cells other than neutrophils (white blood cells)," study senior author, Peter O'Dwyer, professor at University of Pennsylvania, noted.
Advertisement
The study was published in the journal JAMA Oncology.
COMMENTS
Advertisement
Hina Khan, Battling Cancer, Shares Video From Her First Shoot After Chemo Session: "Trying To Hide Stitches" How Hina Khan's Mom Reacted To Actress' Stage 3 Breast Cancer Diagnosis: "Her World Crumbled Down" Hina Khan, Diagnosed With Stage 3 Breast Cancer, Shares Video Of Her New Haircut 25,000 Aspirants For Airport Jobs Paying Rs 22,000: A Mumbai Stampede Scare Puja Khedkar's Disability Document Has Factory Address, Ration Card Proof Prank Goes Wrong: Woman Falls From 3rd Floor In Mumbai Building, Dies "This Is The Final Straw": Elon Musk Moving X And SpaceX Out Of California Urvashi Rautela's Bathroom Video Real Or PR Stunt? Internet Debates Siddaramaiah Deletes Post On 100% Quota Bill, Karnataka Minister Clarifies Track Latest News Live on NDTV.com and get news updates from India and around the world.